Expression of MT2 Receptor in Patients with Gastric Adenocarcinoma and its Relationship with Clinicopathological Features

Nasrabadi, Nafiseh Nasri; Ataee, Ramin; Abediankenari, Saeid; Shokrzadeh, Mohammad; Najafi, Meysam; Hoseini, Seyed Vahid; Jan, Hamed Haghi Amin

doi:10.1007/s12029-013-9552-0

Cited by 24 publications

(21 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The demographic and clinical features of the TCGA patients were summarized according to synthesis/metabolism subgroups in Table S2. Consistent with previous observations, 12,22,23 elderly patients tended to have lower melatonin synthesis/metabolism Index, with significant differences observed in BRCA, LIHC, LUAD, LUSC, PRAD, and SKCM; the high-Index subgroup also tended to have a lower proportion of patients with latestage disease, with significant differences observed in CESC, COAD, HNCS, KIRC, SKCM, and THCA.…”

Section: Characteristics Of the Melatonergic Microenvironment Acrossupporting

confidence: 89%

Pan‐cancer genomic analyses reveal prognostic and immunogenic features of the tumor melatonergic microenvironment across 14 solid cancer types

Lv¹,

Zheng²,

Wang³

et al. 2019

Journal of Pineal Research

View full text Add to dashboard Cite

We performed comprehensive genomic analyses of the melatonergic system within the tumor microenvironment and their clinical relevance across a broad spectrum of solid tumors. RNA‐seq data from The Cancer Genome Atlas (TCGA) of 14 solid tumors representing 6658 human samples were analyzed. The tumor melatonergic system was characterized by the rates of melatonin synthesis and metabolism using a two‐gene expression model (melatonin synthesis/metabolism Index). We calculated three indexes according to different melatonin metabolism isoenzymes (Index‐I [ASMT:CYP1A1], Index‐II [ASMT:CYP1A2], and Index‐III [ASMT:CYP1B1]). Samples of each cancer type were classified into two subgroups (high vs low) based on median values. Clinical outcomes, mutational burden, and neoepitope abundance were analyzed and compared. We found that the ability of the tumor microenvironment to synthesize and accumulate melatonin varied across cancer types and negatively correlated with tumor burden. Kaplan‐Meier survival analyses and multivariable modeling showed that the three indexes played different roles across different cancers and harbored prognostic values in breast cancer (adjusted hazard ratio [AHR]Index‐II = 0.65 [0.44‐0.97]; P = 0.03), cervical cancer (AHRIndex‐I = 0.62 [0.39‐0.98]; P = 0.04), lung squamous cell carcinoma (AHRIndex‐III = 0.75 [0.56‐0.99]; P = 0.04), melanoma (AHRIndex‐I = 0.74 [0.55‐0.98]; P = 0.04), and stomach adenocarcinoma (AHRIndex‐III = 0.68 [0.41‐0.94]; P = 0.02). We further investigated its clinical relevance with tumor immunogenic features (mutational burden and neoantigen abundance), which may predict immunotherapy benefits. We observed significant negative correlations with mutational burden in the majority of tumors (P < 0.05), except cervical cancer, pancreatic adenocarcinoma, and thyroid carcinoma. Our study provides a systematic overview of the oncostatic values of the melatonergic system and highlights the utilization of this simple and promising gene signature as a prognosticator and potential predictor of response to immunotherapy.

show abstract

Section: Characteristics Of the Melatonergic Microenvironment Acrossupporting

confidence: 89%

Pan‐cancer genomic analyses reveal prognostic and immunogenic features of the tumor melatonergic microenvironment across 14 solid cancer types

Lv¹,

Zheng²,

Wang³

et al. 2019

Journal of Pineal Research

View full text Add to dashboard Cite

show abstract

“…Previous studies have reported that melatonin suppresses the proliferation of several cancer cells and can be viewed as an anti-mitogen [14, 89, 90]. Proliferating-cell nuclear antigen (PCNA) is a molecular marker for proliferation because of its role in cell division; the inhibition of PCNA is considered to be a viable anticancer strategy [91].…”

Section: Effect Of Melatonin On Nsclc Cell Proliferationmentioning

confidence: 99%

Melatonin as a potential anticarcinogen for non-small-cell lung cancer

Yang

Fan

et al. 2016

Oncotarget

View full text Add to dashboard Cite

Non-small-cell lung cancer (NSCLC) is a leading cause of death from cancer worldwide. Melatonin, an indoleamine discovered in the pineal gland, exerts pleiotropic anticancer effects against a variety of cancer types. In particular, melatonin may be an important anticancer drug in the treatment of NSCLC. Herein, we review the correlation between the disruption of the melatonin rhythm and NSCLC incidence; we also evaluate the evidence related to the effects of melatonin in inhibiting lung carcinogenesis. Special focus is placed on the oncostatic effects of melatonin, including anti-proliferation, induction of apoptosis, inhibition of invasion and metastasis, and enhancement of immunomodulation. We suggest the drug synergy of melatonin with radio- or chemotherapy for NSCLC could prove to be useful. Taken together, the information complied herein may serve as a comprehensive reference for the anticancer mechanisms of melatonin against NSCLC, and may be helpful for the design of future experimental research and for advancing melatonin as a therapeutic agent for NSCLC.

show abstract

“…Uncontrolled proliferation, which is a significant feature of malignant tumors, leads to tumor progression. Previous studies have found that melatonin inhibits cancer proliferation in many cases and can be viewed as an antimitogen . Using a gastric adenocarcinoma cell line, Zhang et al.…”

Section: Effect Of Melatonin On Gastrointestinal Cancer Cell Prolifermentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…The incidence of gastrointestinal cancer is increasing worldwide and has caused a heavy health burden on society . Gastric cancer accounts for 8% of the total cancer cases and 10% of total cancer deaths worldwide . In addition, the incidence of colorectal cancer has increased; in recent years, it has become one of the most common neoplasms in the world .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Melatonin as a treatment for gastrointestinal cancer: a review

Xin

Jiang

et al. 2015

Journal of Pineal Research

View full text Add to dashboard Cite

Gastrointestinal cancer is a disease that affects the population worldwide with high morbidity and mortality. Melatonin, an endogenously produced molecule, may provide a defense against a variety of cancer types. In particular, the ability of melatonin to inhibit gastrointestinal cancer is substantial. In this review, we first clarify the relationship between the disruption of the melatonin rhythm and gastrointestinal cancer (based on epidemiologic surveys and animal and human studies) and summarize the preventive effect of melatonin on carcinogenesis. Thereafter, the mechanisms through which melatonin exerts its anti-gastrointestinal cancer actions are explained, including inhibition of proliferation, invasion, metastasis, and angiogenesis, and promotion of apoptosis and cancer immunity. Moreover, we discuss the drug synergy effects and the role of melatonin receptors involved in the growth-inhibitory effects on gastrointestinal cancer. Taken together, the information compiled here serves as a comprehensive reference for the antigastrointestinal cancer actions of melatonin that have been identified to date and will hopefully aid in the design of further experimental and clinical studies and increase the awareness of melatonin as a therapeutic agent in cancers of the gastrointestinal tract.

show abstract

Expression of MT2 Receptor in Patients with Gastric Adenocarcinoma and its Relationship with Clinicopathological Features

Cited by 24 publications

References 35 publications

Pan‐cancer genomic analyses reveal prognostic and immunogenic features of the tumor melatonergic microenvironment across 14 solid cancer types

Pan‐cancer genomic analyses reveal prognostic and immunogenic features of the tumor melatonergic microenvironment across 14 solid cancer types

Melatonin as a potential anticarcinogen for non-small-cell lung cancer

Melatonin as a treatment for gastrointestinal cancer: a review

Contact Info

Product

Resources

About